We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $113M
1-Year Est. Return 245.92%
This Fund
S&P 500
This Quarter Est. Return
+2.77%
1 Year Est. Return
+245.92%
3 Year Est. Return
+826.04%
5 Year Est. Return
+770.7%
10 Year Est. Return
–
AUM
$403M
AUM Growth
-$119M
Cap. Flow
-$24.8M
Cap. Flow %
-6.17%
Top 10 Hldgs %
53.89%
Holding
40
New
8
Increased
5
Reduced
7
Closed
11

Top Buys

Rank Stock Value
1
NAUT icon
Nautilus Biotechnolgy
NAUT
+$16.2M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.3M
3
NSTG
NanoString Technologies, Inc.
NSTG
+$11.7M
4
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$11.7M
5
GOSS icon
Gossamer Bio
GOSS
+$10.2M

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$15.9M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$15.1M
3
ITOS
iTeos Therapeutics
ITOS
+$11M
4
NTLA icon
Intellia Therapeutics
NTLA
+$10.3M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 88.56%
2 Miscellaneous 11.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVL
1
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$35.8M 8.89%
58,416
– –
XNTK icon
2
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.01B
$27.1M 6.73%
200,000
-600,000
-75% -$89.8M
NTRA icon
3
Natera
NTRA
$47.3B
$24.8M 6.15%
218,000
– –
FATE icon
4
Fate Therapeutics
FATE
$297M
$23.4M 5.82%
270,000
– –
APLS
5
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$19M 4.71%
+300,000
New +$15.5M
SYRS
6
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$18.7M 4.66%
343,990
+30,000
+10% +$1.78M
ARVN icon
7
Arvinas
ARVN
$614M
$18.5M 4.59%
240,000
+135,747
+130% +$9.42M
CERE
8
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$17.3M 4.3%
675,670
-1,052,920
-61% -$15.1M
RGEN icon
9
Repligen
RGEN
$9.46B
$16.5M 4.09%
82,500
– –
NUVB icon
10
Nuvation Bio
NUVB
$2.39B
$15.9M 3.95%
1,708,091
-291,909
-15% -$3.33M
VRDN icon
11
Viridian Therapeutics
VRDN
$2.6B
$15.7M 3.91%
859,910
+179,142
+26% +$3.07M
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$15.3M 3.81%
+95,000
New +$15.3M
NAUT icon
13
Nautilus Biotechnolgy
NAUT
$115M
$15.2M 3.76%
+1,500,000
New +$16.2M
NTLA icon
14
Intellia Therapeutics
NTLA
$1.79B
$15.1M 3.75%
93,127
-131,873
-59% -$10.3M
CYT
15
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$13.4M 3.33%
+626,843
New +$11.7M
COGT icon
16
Cogent Biosciences
COGT
$6.03B
$13.2M 3.27%
1,622,591
– –
NSTG
17
DELISTED
NanoString Technologies, Inc.
NSTG
$12M 2.98%
+185,000
New +$11.7M
IDYA icon
18
IDEAYA Biosciences
IDYA
$3.85B
$10.7M 2.66%
510,407
+480,407
+1,601% +$9.87M
IOVA icon
19
Iovance Biotherapeutics
IOVA
$3.98B
$10.6M 2.63%
406,986
– –
EPIX
20
DELISTED
ESSA Pharma
EPIX
$10.4M 2.58%
363,185
– –
NVTA
21
DELISTED
Invitae Corporation
NVTA
$10.1M 2.51%
+300,000
New +$9.76M
GOSS icon
22
Gossamer Bio
GOSS
$85.7M
$9.54M 2.37%
+1,175,000
New +$10.2M
AVIR icon
23
Atea Pharmaceuticals
AVIR
$468M
$8.02M 1.99%
373,288
-530,400
-59% -$15.9M
BOLT icon
24
Bolt Biotherapeutics
BOLT
$7.51M
$6.37M 1.58%
20,613
+6,227
+43% +$2.53M
APLS
25
DELISTED
Apellis Pharmaceuticals
APLS
$5.37M 1.33%
85,000
-145,000
-63% -$7.48M
1
2

Similar funds

IA
Invested Advisors State College, Pennsylvania $113M AUM 23.72% 1-Year Est. Return
CPA
Clear Point Advisors Melville, New York $113M AUM 15% 1-Year Est. Return
MBC
Michael Brady & Co Westlake, Ohio $113M AUM
OCM
Objective Capital Management Pepper Pike, Ohio $113M AUM 22.81% 1-Year Est. Return
AWA
Ark Wealth Advisors Yorba Linda, California $113M AUM
TWS
Thomas W. Smith $113M AUM
OFP
OFC Financial Planning Short Hills, New Jersey $113M AUM 26.89% 1-Year Est. Return
IIM
IFC & Insurance Marketing Auburn, California $114M AUM

Ally Bridge Group's Q2 2021 Portfolio in Review

As of Q2 2021, Ally Bridge Group held 40 positions worth $403M, down 23% from $522M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Ally Bridge Group withdrew a net $24.8M in Q2 2021, closing 11 positions and reducing 7 holdings. Its most notable exit was iTeos Therapeutics, an estimated $11M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 79% a quarter earlier, followed by Miscellaneous.

Against the trend, Ally Bridge Group opened a new position in Nautilus Biotechnolgy worth $15.2M.

  • Ally Bridge Group's largest Q2 2021 buy was Nautilus Biotechnolgy: 1,500,000 shares worth $15.2M.
  • Ally Bridge Group added most to IDEAYA Biosciences in Q2 2021, an estimated $9.87M increase.
  • Ally Bridge Group's biggest Q2 2021 reduction was Atea Pharmaceuticals, cutting an estimated $15.9M.
  • Ally Bridge Group fully exited iTeos Therapeutics in Q2 2021, selling an estimated $11M.
  • Ally Bridge Group's ten largest holdings make up 54% of its $403M portfolio in Q2 2021.
  • Ally Bridge Group opened 8 new positions and closed 11 in Q2 2021.
  • Ally Bridge Group's portfolio value fell 23% quarter-over-quarter to $403M.

Based on Ally Bridge Group's 13F filing for Q2 2021, filed 16 Aug 2021.